{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-01-072025-01-072025-01-092025-01-092025-01-102025-01-10341218866442200
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-01-072025-01-072025-01-092025-01-092025-01-102025-01-1015418866442200
Download SVG
Download PNG
Download CSV
Alzheimer’s drug development is gaining investor attention, with Biogen's Leqembi and Eli Lilly's Kisunla leading the market despite their limitations in reversing the disease. Novo Nordisk is exploring semaglutide's potential benefits for early Alzheimer’s patients, while Roche and UCB are assessing new treatments amid mixed trial results. The landscape is dynamic, with significant opportunities for firms that can deliver effective therapies.
Tele2 AB's stock fell 2.8% following a downgrade to "sell" by UBS, which cited weak momentum and concerns over earnings from free cash flow. The brokerage lowered its price target to SEK 102, predicting challenges due to declining service revenue, mobile pricing pressures, and increased cash taxes. Despite potential long-term upside from regulatory changes, UBS warns that Tele2 may struggle to meet dividend commitments amid rising competition in the Nordic telecom sector.
Tele2 AB's stock fell 2.8% following a downgrade to "sell" by UBS, which cited weak momentum and concerns over earnings from free cash flow. The brokerage lowered its price target to SEK 102, predicting challenges due to declining service revenue in Sweden, increased cash taxes, and ongoing capital expenditures. While there may be long-term upside from regulatory changes, UBS warns that Tele2 is unlikely to meet dividend commitments without significant pressure on cash flow.
UBS has downgraded Tele2 from neutral to sell, reducing its target price to SEK 102 due to concerns over the company's declining momentum and dividend coverage compared to competitors like Telenor and Telia. The bank forecasts Tele2's free cash flow for 2025 and 2026 to be 7% and 10% below consensus, citing the shutdown of legacy TV services and tax uncertainties as contributing factors. Despite these challenges, UBS notes potential long-term benefits, including focused market exposure and an attractive dividend policy, while favoring Telenor in the Nordic telecom sector.
E.ON SE, a leading electricity and gas producer and distributor, has received a Buy rating from UBS. The company's net sales are primarily derived from electric energy (61.7%) and gas distribution (25.6%), with a geographical distribution of sales mainly in Germany (40%) and the United Kingdom (35.4%).
UBS Group has lowered its price target for Lundin Mining (TSE:LUN) from C$17.00 to C$15.50, indicating a potential upside of 22.34%. Despite a "Moderate Buy" rating, analysts have mixed views, with six holding and nine giving buy ratings. The company reported a quarterly earnings miss, with C$0.12 per share against expectations of C$0.24.
Boliden's shares rose 2.5% after UBS upgraded its recommendation from sell to neutral, increasing the target price from SEK 300 to 310. The reassessment follows Boliden's acquisition of Lundin Mining's European mines, which UBS views as strategically beneficial and likely to enhance earnings through synergies. The transaction is expected to close in mid-2025.
Boliden shares rose over 3% after UBS upgraded the stock to a 'neutral' rating, citing a favorable outlook following the acquisition of Neves Corvo and Zinkgruvan. While the deal is expected to enhance earnings, challenges such as declining mined grades and a tough smelting outlook persist. UBS raised its price target to SEK310 per share, indicating a more balanced risk-reward profile despite ongoing hurdles.
Boliden shares rose over 3% after UBS upgraded the stock to a 'neutral' rating, citing a favorable outlook following the acquisition of Neves Corvo and Zinkgruvan. While the deal is expected to enhance earnings, challenges such as declining mined grades and a tough smelting outlook persist. UBS raised its price target to SEK310 per share, indicating a more balanced risk-reward profile despite ongoing hurdles.
UBS has upgraded Boliden AB's stock rating from Sell to Neutral, raising the price target to SEK310. Despite challenges like lower mined grades and potential equity issuance in 2025, the analyst highlights the positive impact of recent acquisitions and anticipated improvements in mining grades and smelter earnings. The assessment suggests a more balanced risk-reward scenario for Boliden moving forward.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.